drugset
drugset / Trial / NCT05097079

Efficacy and Safety Study of MYOBLOC in the Treatment of Sialorrhea in Pediatric Subjects

NCT05097079 ↗

Phase 3 Withdrawn Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate the efficacy and safety of MYOBLOC for the treatment of chronic sialorrhea in pediatric subjects.

Timeline

Start
2021-11
Primary completion
2023-05
Completion
2023-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum Toxin Type B Unknown 60 iu/kg Other
Subject Botulinum Toxin Type B Unknown 100 iu/kg Other

Indications

No indication recorded.